H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials.

ABSTRACT:

Introduction

Hemagglutination inhibition (HAI) antibody titers to seasonal influenza strains are important surrogates for vaccine-elicited protection. However, HAI assays can be variable across labs, with low sensitivity across diverse viruses due to lack of standardization. Performing qualification of these assays on a strain specific level enables the precise and accurate quantification of HAI titers. Influenza A (H3N2) continues to be a predominant circulating subtype in most countries in Europe and North America since 1968 and is thus a focus of influenza vaccine research.

Methods

As a part of the National Institutes of Health (NIH)-funded Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, we report on the identification of a robust assay design, rigoro

SUBMITTER: Sawant S 

PROVIDER: S-EPMC10117676 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature